title: Pharmacokinetics and Pharmacodynamics of Afamelanotide and its Clinical Use in Treating Dermatologic Disorders.
abstract: Afamelanotide, the first α-melanocyte-stimulating hormone (MSH) analogue, synthesized in 1980, was broadly investigated in all aspects of pigmentation because its activity and stability were higher than the natural hormone. Afamelanotide binds to the melanocortin-1 receptor (MC1R), and MC1R signaling increases melanin synthesis, induces antioxidant activities, enhances DNA repair processes and modulates inflammation. The loss-of-function variants of the MC1R present in fair-skinned Caucasians are less effectively activated by the natural hormone. Afamelanotide was the first α-MSH analogue to be applied to human volunteers. Ten daily doses of between 0.08 and 0.21 mg/kg in saline injected subcutaneously resulted in long-lasting skin pigmentation and enabled basic pharmacokinetics. Subcutaneous application had full bioavailability, but neither oral nor transdermal application resulted in measurable plasma concentrations or pigmentation response. Two trials in human volunteers showed that neither MC1R variants nor fair skin reduced the afamelanotide-induced increase in skin pigmentation. A controlled-release formulation optimizes administration in man and is effective at a lower dose than the daily saline injections. Promising therapeutic results were published in polymorphic light eruption, erythropoietic protoporphyria (EPP), solar urticaria, Hailey-Hailey disease and vitiligo. In 2014, afamelanotide was approved by the European Medicines Agency for the prevention of phototoxicity in adult patients with EPP. No late effects were reported in volunteers 25 years after the first exposure or after continuous long-term application of up to 8 years in EPP patients, and an immunogenic potential has been excluded. Generally, adverse effects were benign in all trials.
authors.affiliation: Stadtspital Triemli, Porphyria Outpatient Clinics, Zurich, Switzerland. elisabeth.minder@triemli.zuerich.ch.
authors.forename: Elisabeth I
authors.initials: EI
authors.lastname: Minder
authors.affiliation: Stadtspital Triemli, Institute of Laboratory Medicine, Zurich, Switzerland.
authors.forename: Jasmin
authors.initials: J
authors.lastname: Barman-Aksoezen
authors.affiliation: Stadtspital Triemli, Institute of Laboratory Medicine, Zurich, Switzerland.
authors.forename: Xiaoye
authors.initials: X
authors.lastname: Schneider-Yin
mesh_terms: D000279:Administration, Cutaneous; D000328:Adult; D002986:Clinical Trials as Topic / Q000379:methods; D004260:DNA Repair / Q000187:drug effects; D003692:Delayed-Action Preparations; D017484:Dermatitis, Phototoxic / Q000517:prevention & control; D003879:Dermatologic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics* / Q000494:pharmacology; D005260:Female; D006801:Humans; D008297:Male; D016506:Pemphigus, Benign Familial / Q000188:drug therapy; D046351:Protoporphyria, Erythropoietic / Q000188:drug therapy; D044102:Receptor, Melanocortin, Type 1 / Q000819:agonists* / Q000187:drug effects / Q000378:metabolism; D012871:Skin Diseases / Q000188:drug therapy*; D012880:Skin Pigmentation / Q000187:drug effects; D014581:Urticaria / Q000188:drug therapy; D014820:Vitiligo / Q000188:drug therapy; D000521:alpha-MSH / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000493:pharmacokinetics* / Q000494:pharmacology
chemical_list: D003692:Delayed-Action Preparations; D003879:Dermatologic Agents; D044102:Receptor, Melanocortin, Type 1; D000521:alpha-MSH; C534526:afamelanotide